Last reviewed · How we verify
NCT05557162
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
NA trial testing AI ECG Amyloid algorithm in Cardiac Amyloidosis in 20,143 participants. Completed in 23 July 2025.
23 July 2025
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 20,143 |
| Start date | 19 June 2023 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- AI ECG Amyloid algorithm
Conditions studied
- Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives.
Caponetti AG, Accietto A, Saturi G, Ponziani A, et al · · 2023 · cited 5× · PMID 36970351 · DOI 10.3389/fcvm.2023.1146725
Verify or expand the search:
- PubMed search for NCT05557162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Amyloidosis
Currently open trials in the same condition.
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06788535 — Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis · Phase 3 · active not recruiting
- NCT06458374 — ATTR Cardiac Amyloidosis in a Selected Population · recruiting
- NCT06427304 — Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure · recruiting
- NCT06907836 — Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05557162 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05557162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing